Ex Vivo Effect of Varespladib on Secretory Phospholipase A2 Alveolar Activity in Infants with ARDS
暂无分享,去创建一个
P. Cogo | M. Piastra | G. Conti | E. Capoluongo | B. Giardina | A. Minucci | L. Marzano | D. De Luca | F. Vendittelli | Leonarda Gentile | L. Gentile
[1] G. Conti,et al. Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury , 2012, Journal of clinical pharmacology.
[2] P. Cogo,et al. Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review , 2011, European Respiratory Journal.
[3] P. Cogo,et al. Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[4] D. Waters,et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. , 2010, Journal of the American College of Cardiology.
[5] A. Postle,et al. Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[6] A. Randolph. Management of acute lung injury and acute respiratory distress syndrome in children: A different perspective , 2009 .
[7] A. Randolph. Management of acute lung injury and acute respiratory distress syndrome in children. , 2009, Critical care medicine.
[8] L. Ware,et al. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. , 2009, Chest.
[9] D. Waters,et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial , 2009, The Lancet.
[10] M. Gelb,et al. Biochemistry and physiology of mammalian secreted phospholipases A2. , 2008, Annual review of biochemistry.
[11] J. Moran,et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis , 2008, BMJ : British Medical Journal.
[12] S. Fleischer,et al. Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots , 2007, Lipids.
[13] C. Romagnoli,et al. Epithelial lining fluid free IGF-I-to-PAPP-A ratio is associated with bronchopulmonary dysplasia in preterm infants. , 2007, American journal of physiology. Endocrinology and metabolism.
[14] Richard N. Shiffman,et al. Diagnosis and management of bronchiolitis. , 2006, Pediatrics.
[15] M. Gelb,et al. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. , 2006, Journal of medicinal chemistry.
[16] H. Bauchner,et al. Diagnosis and Management of Bronchiolitis , 2006, Pediatrics.
[17] L. Touqui,et al. Relationship between pressure-volume curve and markers for collagen turn-over in early acute respiratory distress syndrome , 2006, Intensive Care Medicine.
[18] G. Ansari,et al. RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. , 2005, Virology.
[19] A. Dmitrienko,et al. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis* , 2005, Critical care medicine.
[20] L. Touqui,et al. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome* , 2005, Critical care medicine.
[21] M. Seeds,et al. Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[22] J R Prous,et al. Gateways to clinical trials. , 2005, Methods and findings in experimental and clinical pharmacology.
[23] L. Monte,et al. [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.
[24] V. Vashishtha. Brief profile of an epidemic of acute encephalopathy in Western Uttar Pradesh. , 2003, Indian pediatrics.
[25] J. Balsinde,et al. Amplification Mechanisms of Inflammation: Paracrine Stimulation of Arachidonic Acid Mobilization by Secreted Phospholipase A2 Is Regulated by Cytosolic Phospholipase A2-Derived Hydroperoxyeicosatetraenoic Acid1 , 2003, The Journal of Immunology.
[26] J. Bonventre,et al. Cross-talk between Cytosolic Phospholipase A2α (cPLA2α) and Secretory Phospholipase A2 (sPLA2) in Hydrogen Peroxide-induced Arachidonic Acid Release in Murine Mesangial Cells , 2003, Journal of Biological Chemistry.
[27] L. Touqui,et al. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury , 2003, European Respiratory Journal.
[28] Stephen F. Lowry,et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure , 2003, Critical care medicine.
[29] Z. İlçe,et al. Modified Ventilatory Index (MVI) in newborns with congenital diaphragmatic hernia (CDH). , 2003, Indian pediatrics.
[30] A. Matsukawa,et al. Effect of methylprednisolone on phospholipase A(2) activity and lung surfactant degradation in acute lung injury in rabbits. , 2001, European journal of pharmacology.
[31] C. Ruppert,et al. Surfactant alteration and replacement in acute respiratory distress syndrome , 2001, Respiratory research.
[32] A. Matsukawa,et al. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection , 2001, Critical care medicine.
[33] N. Goldsack,et al. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. , 2000, American journal of respiratory and critical care medicine.
[34] F. Ratjen,et al. Bronchoalveolar lavage in children , 2000 .
[35] A. Clément,et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. , 2000 .
[36] D. Thickett,et al. Changes in collagen turnover in early acute respiratory distress syndrome. , 1999, American journal of respiratory and critical care medicine.
[37] A. Matsukawa,et al. Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits. , 1999, American journal of respiratory and critical care medicine.
[38] L. Touqui,et al. A role for phospholipase A2 in ARDS pathogenesis. , 1999, Molecular medicine today.
[39] N. Roehm,et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. , 1999, The Journal of pharmacology and experimental therapeutics.
[40] A. Numa,et al. Acute respiratory distress syndrome caused by respiratory syncytial virus , 1997, Pediatric pulmonology.
[41] B. Thompson,et al. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. , 1995, The American journal of physiology.
[42] J.-P. Wery,et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.
[43] M. Lamy,et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.
[44] E. Dennis,et al. Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader. , 1992, Analytical biochemistry.
[45] A. Clément,et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. , 2000 .